Welcome to our dedicated page for Cormedix news (Ticker: CRMD), a resource for investors and traders seeking the latest updates and insights on Cormedix stock.
CorMedix Inc. develops and commercializes therapeutic products for life-threatening conditions, with a U.S. commercial focus in institutional settings of care. Its recurring news centers on DefenCath, a taurolidine and heparin product used to prevent catheter-related bloodstream infections in adult hemodialysis patients with central venous catheters, and on the specialty pharmaceutical portfolio added through the completed Melinta Therapeutics acquisition.
Company updates also cover anti-infective and hospital-focused products such as MINOCIN for Injection, REZZAYO, VABOMERE, ORBACTIV, BAXDELA and KIMYRSA, as well as TOPROL-XL. News themes include operating and financial results, commercial execution, clinical and regulatory disclosures for expanded product uses, shareholder voting matters, governance updates, investor conference activity and capital actions such as share repurchase authorization.
CorMedix (Nasdaq: CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening diseases, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The event will be held virtually from April 7-10, 2025.
The company's management will engage in a Fireside Chat scheduled for Tuesday, April 8, 2025, at 2:15 p.m. EDT. This participation aligns with CorMedix's ongoing efforts to maintain investor relations and industry presence.
CorMedix (NASDAQ: CRMD) reported strong financial results for Q4 and full year 2024, marking its first profitable commercial quarter. The company achieved Q4 net revenue of $31.2 million and full-year revenue of $43.5 million, primarily driven by DefenCath sales since its outpatient launch in July 2024.
Q4 highlights include net income of $13.5 million and adjusted EBITDA of $15.3 million. The company ended 2024 with $51.7 million in cash and short-term investments. CorMedix provided preliminary guidance for H1 2025 with expected net revenue of $50-60 million, including over $33 million in Q1.
Key developments include partnering with Syneos Health for inpatient sales team building and WSI for VA facilities marketing. The company is preparing to commence a Phase 3 study of DefenCath in Total Parenteral Nutrition patients in Q2 2025, with a pending FDA Orphan Drug Status application.
CorMedix (Nasdaq: CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening diseases, has scheduled its Q4 and Full Year 2024 financial results announcement. The company will release its financial performance report before market opens on March 25, 2025, followed by a corporate update conference call at 8:30am Eastern Time.
CorMedix (Nasdaq: CRMD), a biopharmaceutical company, has announced a collaboration with WSI PBG, a subsidiary of Golden State Medical Supply, to promote DefenCath® to healthcare providers in facilities operated by the Department of Veterans Affairs (VA) and other federal facilities.
This partnership aims to enhance access to critical therapies for approximately 40,000 veterans living with end-stage renal disease (ESRD) and other beneficiaries of federal programs. WSI PBG will leverage its expertise in navigating VA and federal facilities, including access, procurement processes, and regulations, to meet the unique needs of these healthcare systems.
CorMedix and WSI PBG are committed to improving health outcomes by providing increased access to DefenCath for patients at VA and other federal facilities. Joe Todisco, CEO of CorMedix, expressed excitement about the collaboration, citing WSI PBG's deep understanding of the federal healthcare landscape as a key factor in enhancing access to DefenCath and ensuring equitable care for veterans and other federal healthcare beneficiaries.
CorMedix (NASDAQ: CRMD) reports strong preliminary Q4 2024 results with unaudited net revenue of approximately $31 million and full-year 2024 revenue of $43 million. Q4 adjusted EBITDA is expected to exceed $12 million, achieving the company's breakeven target by year-end 2024.
The company has secured over $25 million in open purchase orders for Q1 2025 delivery and is actively shipping DefenCath to three midsized dialysis operators. CorMedix plans to expand into the inpatient hospital segment in Q1 2025 through a partnership with Syneos Health for dedicated sales team deployment. The company projects FY 2025 operating expenses of $72-78 million, with increased R&D spending for clinical initiatives.
As of December 31, 2024, CorMedix maintains a strong financial position with approximately $52 million in cash and short-term investments.
CorMedix Inc. (CRMD) has announced its upcoming addition to the Nasdaq Biotechnology Index (NBI), effective before market open on Monday, December 23, 2024. The NBI is a modified market capitalization weighted index tracking NASDAQ-listed biotechnology and pharmaceutical companies. Inclusion in the index is based on specific eligibility criteria, including minimum market capitalization and average daily trading volume requirements. The index undergoes annual reconstitution in December.
CorMedix welcomes significant CMS policy updates that will enhance hemodialysis patients' access to innovative therapies. Starting January 2025, CMMI's Kidney Care Choices model will exclude TDAPA payments from financial calculations, facilitating access to new drugs including DefenCath®. This change affects over 30% of ESRD patients in the US currently enrolled in KCC programs, removing financial barriers to innovative drug utilization and ensuring patient care choices aren't by cost considerations.
CorMedix (Nasdaq: CRMD) announced its participation in the Truist Securities BioPharma Symposium scheduled for November 7, 2024, in New York City. The event will feature one-on-one meetings at the Lotte New York Palace Hotel. CorMedix is focused on commercializing DefenCath®, their lead product approved by the FDA in November 2023. The company has already launched DefenCath in inpatient settings in April 2024 and expanded to outpatient settings in July 2024. They plan to further develop DefenCath as a catheter lock solution for additional patient populations.
CorMedix reported Q3 2024 financial results with net revenue of $11.5 million in its first full quarter of DefenCath sales. The company secured commercial agreements covering approximately 60% of US outpatient dialysis centers. Net loss decreased to $2.8 million ($0.05 per share) compared to $9.7 million ($0.17 per share) in Q3 2023. Operating expenses increased 34% to $14.1 million. Cash position stands at $46.0 million, which the company believes is sufficient for at least twelve months of operations. CorMedix is preparing to expand DefenCath indications beyond adult hemodialysis with several clinical initiatives planned for early 2025.
CorMedix presented new hospital admission and health economic data at ASN Kidney Week 2024, analyzing bloodstream infections (BSIs) in hemodialysis patients using central venous catheters. The study of 91,448 patients revealed that 25% were admitted with BSIs. Key findings showed median hospital stays of 16 days, with 53.8% requiring ICU care. The median total cost per admission was $157,000, with $65,000 for ICU care. The study reported 10.3% in-hospital mortality and 26.8% readmission rates within 90 days. Patient demographics showed 58.2% white, 27.1% black, with 47% from disadvantaged neighborhoods.